mardi 9 mai 2017

Onco Actu du 9 mai 2017

2. Etiologie

Citizen science often overstates ‘cancer clusters’ like the one linked to artificial turf [STAT]

2.6 Etiologie - Environnement

Greater total pollution exposure tied to higher cancer risk [Reuters]

3. Prévention

Personal Health: How to Lower Breast Cancer Risk [NY Times]

3.1.1 Tabac - e-cigs

The shadow of Big Tobacco looms over e-cigarettes and harm reduction [STAT]

More than half of British vapers have now given up smoking tobacco [Cancer Research UK]

E-cigarette companies fined over false claims about toxic chemicals [The Guardian]

Majority of vapers have quit tobacco – survey [The Guardian]

3.5 Prévention - UV

Sun Awareness Week: 10 new sun safety myths debunked [Cancer Research UK]

3.8 Prévention - Alimentation

14: The Unmentioned Number in the Prostate Cancer/Coffee Story [ACS]

4. Dépistage, diagnostic et pronostic

Study finds low rate of cancer screening among transplant patients [ecancernews]

4.10 Dép., diag. & prono. - Poumon

Million-Dollar Prize Hints at How Machine Learning May Someday Spot Cancer [MIT Technology Review]

4.12 Biopsies liquides

Roche launches AVENIO ctDNA Analysis Kits for Oncology Research [Roche]

Blood test may lead to targeted therapy for prostate cancer [NHS Choices]

5. Traitements

Study suggests a role for radiotherapy for extending the lives of pancreatic cancer patients [ESTRO]

Taking a potential new breast cancer treatment from the lab to the clinic [Cancer Research UK]

Head and Neck Cancer Recurrence Following Radiation Associated With High Tumor PD-L1 Expression [AACR]

5.10 Traitements - Essais

ASCO and NCI Collaboration Finds Widespread Benefits of Centralizing Coverage Analyses for Multi-Site Clinical Trials [ASCO]

5.12.1 Immunothérapies - partenariats

Regeneron pens Inovio I-O combo cocktail pact for aggressive brain tumors [FierceBiotech]

5.12.2 Immunothérapies - CAR-T

Investors spooked by Kite CAR-T death, but biotech remains confident [FierceBiotech]

Kite CAR-T Death: An Unwelcome Mystery as FDA Mulls Approval [Xconomy]

Kite’s Latest News [In the Pipeline]

Nanoparticles Create Effective CAR T Cells in Living Mice [NCI]

Kite Pharma Discloses CAR-T Patient Death, Rattling Investors [The Street]

One of Kite Pharma’s CAR-T patients died from cerebral edema, triggering a safety alarm [EndPoints]

5.12.6 Immunothérapies - AMM

European Commission Approves KEYTRUDA® (pembrolizumab) for Patients with Relapsed or Refractory Classical Hodgkin Lymphoma Who Failed Autologous Stem Cell Transplant and Brentuximab Vedotin (BV), or Who are Transplant-Ineligible and Have Failed BV [Merck]

5.2 Pharma

OncoMed racks up three straight clinical disasters as lead drug implodes [EndPoints]

5.2.1 Pharma - Partenariats

Seattle Genetics Terminates License Agreement with Immunomedics for Sacituzumab Govitecan (IMMU-132) [Seattle Genetics]

Seattle kills off $2B Immunomedics deal as biotech’s CEO and founder axed [FierceBiotech]

Seattle Genetics throws in the towel on $2B Immunomedics deal, CEO and CSO axed in settlement [EndPoints]

5.3 Traitements - FDA, EMA, NICE...

Involving patients in discussions on benefits and risks of medicines [EMA]

5.3.4 Traitements - AMM (FDA, EMA)

FDA OKs Medrobotics’ robotic system for colorectal surgery [FierceBiotech]

6.1 Observation

Type of prostate cancer surgery tied to later quality of life [Reuters]

6.10 Politiques

Scientists relieved by Emmanuel Macron’s French election victory [Nature]

6.10.1 Politiques (USA)

Life Science Leaders Meet at White House [The Scientist]

6.6 Publications

Introducing the Doing the Right Thing award, honoring those who clean up the scientific literature [STAT]

6.8 Communication

“Less is more” theme from breast cancer conference attracts little mainstream news coverage [HealthNewsReview]

6.9 Controverses

French plan to create €5-billion science ‘super-campus’ in disarray [Nature]